A Phase III Observer-Blind, Randomized, Controlled, Multicenter Study to Evaluate Safety, Tolerability, and Immunogenicity of Two Trivalent Subunit Inactivated Influenza Vaccines (Agrippal® and Fluvirin®) in Healthy Children Aged 3 to 8 years, in Healthy Children/Adolescents Aged 9 to 17 Years And in Healthy Adults Aged 18 to 64 Years

Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2014
This article has no abstract
Epistemonikos ID: 615dc3d5009080c32ddc2f73f4fae2dddaf81dcb
First added on: Jan 22, 2025